- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.12.25 | FDA clears GSK's twice-yearly asthma drug | ||
| 17.12.25 | Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection | ||
| 17.12.25 | RA Capital backs drug for rare kind of chronic pain | ||
| 17.12.25 | Addition emerges with $100M to make gene therapies for chronic and rare diseases | ||
| 16.12.25 | Developing a path forward in cancer cachexia | ||
| 16.12.25 | Nektar sees silver lining as autoimmune drug 'narrowly' misses in alopecia study | ||
| 16.12.25 | FDA 'proactively' hands J&J a voucher; Pfizer issues 2026 forecasts | ||
| 16.12.25 | Enhertu combo cleared for use in frontline breast cancer | ||
| 16.12.25 | 'Zombie' biotech buyer Xoma to acquire Generation Bio | ||
| 15.12.25 | Argenx falters in effort to expand immune drug's use | ||
| 15.12.25 | Sanofi MS drug hits two setbacks | ||
| 15.12.25 | Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease | ||
| 15.12.25 | How rare-disease teams can fine-tune COAs to bridge meaningful change and measurable progress | ||
| 12.12.25 | Arcus cancels work on Gilead-partnered cancer combo after trial setback | ||
| 12.12.25 | Praxis tees up another approval filing; Geron turns to layoffs | ||
| 11.12.25 | AC Immune posts positive data for Parkinson's immunotherapy | ||
| 11.12.25 | Biotech venture firm Apple Tree goes bankrupt amid dispute with billionaire backer | ||
| 11.12.25 | Lilly's three-pronged drug puts obesity field 'on notice' | ||
| 11.12.25 | Crapo, Cassidy propose enhanced ACA subsidy alternative | ||
| 11.12.25 | Prolynx banks $70M for longer-lasting obesity drugs | ||
| 10.12.25 | FDA approves first drug in National Priority Voucher program | ||
| 10.12.25 | A former Roivant spinout bets on AI-designed drugs for immune conditions | ||
| 09.12.25 | Novartis notches another win for drug acquired in MorphoSys deal | ||
| 09.12.25 | Pfizer dips into China for another try at an obesity pill | ||
| 09.12.25 | J&J's 'remarkable' Tecvayli data support earlier use in multiple myeloma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .